Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of ...

Dupixent demonstrated superior efficacy in reducing nasal polyp size and improving smell in CRSwNP, as well as enhancing lung function and disease control in asthma, with benefits observed as ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

A new Canadian real-world study, ACTIONS (chAracterizing oral Corticosteroid use in patients with chronic rhInOsinusitis with ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed ...

This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...